Ane-Victoria Idland1,2, Torgeir Bruun Wyller1,3, Randi Støen4, Lars Magne Eri5,6, Frede Frihagen7, Johan Ræder4,5, Farrukh Abbas Chaudhry8, Oskar Hansson9,10, Henrik Zetterberg11,12, Kaj Blennow11, Nenad Bogdanovic3,5, Anne Brækhus3,13, Leiv Otto Watne1,8. 1. Oslo Delirium Research Group, Department of Geriatric Medicine, Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 2. Research Group for Lifespan Changes in Brain and Cognition, Department of Psychology, University of Oslo, Oslo, Norway. 3. Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway. 4. Department of Anesthesiology, Oslo University Hospital, Oslo, Norway. 5. Institute of Clinical Medicine, University of Oslo, Oslo, Norway. 6. Department of Urology, Oslo University Hospital, Oslo, Norway. 7. Department of Orthopedic Surgery, Oslo University Hospital, Oslo, Norway. 8. Institute of Basic Medical Sciences, University of Oslo, Oslo, Norway. 9. Department of Clinical Sciences, Lund University, Lund, Sweden. 10. Memory Clinic, Skåne University Hospital, Lund, Sweden. 11. Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden. 12. Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK. 13. Norwegian National Advisory Unit on Ageing and Health, Vestfold Hospital Trust, Tberg, Tønsnerg, Norway.
Abstract
BACKGROUND: The clinical relevance of brain β-amyloidosis in older adults without dementia is not established. As delirium and dementia are strongly related, studies on patients with delirium may give pathophysiological clues. OBJECTIVE: To determine whether the Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers amyloid-β 1-42 (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau) are associated with delirium in hip fracture patients with and without dementia. METHODS:CSF was collected in conjunction to spinal anesthesia in 129 patients. Delirium was assessed using the Confusion Assessment Method once daily in all patients, both pre- and postoperatively. The diagnosis of dementia at admission was based upon clinical consensus. CSF levels of Aβ42, T-tau, and P-tau were analyzed. RESULTS: In patients without dementia, we found lower CSF Aβ42 levels (median, 310 ng/L versus 489 ng/L, p = 0.006), higher T-tau levels (median, 505 ng/L versus 351 ng/L, p = 0.02), but no change in P-tau in patients who developed delirium (n = 16) compared to those who remained lucid (n = 49). Delirious patients also had lower ratios of Aβ42 to T-tau (p < 0.001) and P-tau (p = 0.001) relative to those without delirium. CSF Aβ42 and T-tau remained significantly associated with delirium status in adjusted analyses. In patients with dementia, CSF biomarker levels did not differ between those with (n = 54) and without delirium (n = 10). CONCLUSION: The reduction in CSF Aβ42, indicating β-amyloidosis, and increase in T-tau, indicating neurodegeneration, in hip fracture patients without dementia developing delirium indicates that preclinical AD brain pathology is clinically relevant and possibly plays a role in delirium pathophysiology.
RCT Entities:
BACKGROUND: The clinical relevance of brain β-amyloidosis in older adults without dementia is not established. As delirium and dementia are strongly related, studies on patients with delirium may give pathophysiological clues. OBJECTIVE: To determine whether the Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers amyloid-β 1-42 (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau) are associated with delirium in hip fracturepatients with and without dementia. METHODS: CSF was collected in conjunction to spinal anesthesia in 129 patients. Delirium was assessed using the Confusion Assessment Method once daily in all patients, both pre- and postoperatively. The diagnosis of dementia at admission was based upon clinical consensus. CSF levels of Aβ42, T-tau, and P-tau were analyzed. RESULTS: In patients without dementia, we found lower CSF Aβ42 levels (median, 310 ng/L versus 489 ng/L, p = 0.006), higher T-tau levels (median, 505 ng/L versus 351 ng/L, p = 0.02), but no change in P-tau in patients who developed delirium (n = 16) compared to those who remained lucid (n = 49). Delirious patients also had lower ratios of Aβ42 to T-tau (p < 0.001) and P-tau (p = 0.001) relative to those without delirium. CSF Aβ42 and T-tau remained significantly associated with delirium status in adjusted analyses. In patients with dementia, CSF biomarker levels did not differ between those with (n = 54) and without delirium (n = 10). CONCLUSION: The reduction in CSF Aβ42, indicating β-amyloidosis, and increase in T-tau, indicating neurodegeneration, in hip fracturepatients without dementia developing delirium indicates that preclinical AD brain pathology is clinically relevant and possibly plays a role in delirium pathophysiology.
Authors: Tamara G Fong; Sarinnapha M Vasunilashorn; Towia Libermann; Edward R Marcantonio; Sharon K Inouye Journal: Int J Geriatr Psychiatry Date: 2019-03-15 Impact factor: 3.485
Authors: Annie M Racine; Tamara G Fong; Thomas G Travison; Richard N Jones; Yun Gou; Sarinnapha M Vasunilashorn; Edward R Marcantonio; David C Alsop; Sharon K Inouye; Bradford C Dickerson Journal: Neurobiol Aging Date: 2017-08-04 Impact factor: 4.673
Authors: Annie M Racine; Alexandra Touroutoglou; Tatiana Abrantes; Bonnie Wong; Tamara G Fong; Michele Cavallari; Thomas G Travison; Yun Gou; Edward R Marcantonio; David C Alsop; Richard N Jones; Sharon K Inouye; Bradford C Dickerson Journal: J Alzheimers Dis Date: 2020 Impact factor: 4.472
Authors: Sophia Wang; Ryan Greene; Yiqing Song; Carol Chan; Heidi Lindroth; Sikandar Khan; Gabriel Rios; Robert D Sanders; Babar Khan Journal: Int Psychogeriatr Date: 2022-01-17 Impact factor: 7.191
Authors: Carol K Chan; Frederick E Sieber; Kaj Blennow; Sharon K Inouye; Geoffrey Kahn; Jeannie-Marie S Leoutsakos; Edward R Marcantonio; Karin J Neufeld; Paul B Rosenberg; Nae-Yuh Wang; Henrik Zetterberg; Constantine G Lyketsos; Esther S Oh Journal: Am J Geriatr Psychiatry Date: 2021-02-04 Impact factor: 4.105
Authors: Karen Roksund Hov; Nils Bolstad; Ane-Victoria Idland; Henrik Zetterberg; Kaj Blennow; Farrukh A Chaudhry; Frede Frihagen; Johan Ræder; Torgeir Bruun Wyller; Leiv Otto Watne Journal: Dement Geriatr Cogn Dis Extra Date: 2017-11-09
Authors: Kristi Henjum; Else Quist-Paulsen; Henrik Zetterberg; Kaj Blennow; Lars N G Nilsson; Leiv Otto Watne Journal: J Neuroinflammation Date: 2018-11-03 Impact factor: 8.322
Authors: Esther S Oh; Kaj Blennow; George E Bigelow; Sharon K Inouye; Edward R Marcantonio; Karin J Neufeld; Paul B Rosenberg; Juan C Troncoso; Nae-Yuh Wang; Henrik Zetterberg; Frederick E Sieber; Constantine G Lyketsos Journal: PLoS One Date: 2018-09-25 Impact factor: 3.240